Glenmark Pharma is expected to report a profit after tax of Rs 106 crore in the third quarter of FY12, rising 89% as compared to Rs 56 crore in previous quarter.
Revenues are seen going down 10% to Rs 952.5 crore from Rs 1,056 crore quarter-on-quarter.
EBITDA is likely to fall 9% to Rs 205 crore in the quarter ended December FY12 versus Rs 226 crore in an earlier quarter. Operating profit margin is expected to be at 21.5% versus 21.4% QoQ and 23% YoY.
On year-on-year basis, revenues are likely to go up by 25.6% and EBITDA is seen going up by 17.6%. But, profit after tax is expected to go down 3.2%.
Company will report numbers according to International Financial Reporting Standards (IFRS) hence there might be variations while comparing YoY, but QoQ is comparable. Highlights
- PAT figures excludes MTM losses this quarter
- Some analysts estimating a loss on the bottomline due to MTM as well
- In Q2FY12 forex loss was Rs 85 crore
- Could see licensing fee of USD 5 million related to successful completion of Phase I trials for GRC 15300
* Q2FY12 Licensing income was Rs 120 crore from Sanofi on
- Revenues growth led by US markets on the back of new launches especially Malarone where company has exclusivity
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
